Replies to post #88486 on $heff's $tation of $tocks & $olid DD

[crudeoil24]

Geron (NASDAQ:GERN) +20.4% PM on news that the New England Journal of Medicine would publish two papers showing positive results for GERN's flagship drug imetelstat, an inhibitor of the telomerase cancer cell enzyme.In two mid-stage clinical trials, GERN said the use of imetelstat suggested it works against malignant cells that cause essential thrombocythemia, a disease in which the body produces too many blood platelets, and against myelofibrosis, a bone marrow disease that disrupts the body's production of blood cells.